Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Stock Chart & Stats
$43.95
$0.17(0.50%)
At close: 4:00 PM EST
$43.95
$0.17(0.50%)
Day’s Range― - ―
52-Week Range$32.38 - $49.62
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.36M
Market Cap
$11.52B
Enterprise Value$11.25B
Total Cash (Recent Filing)$988.53M
Total Debt (Recent Filing)$176.46M
Price to Earnings (P/E)15.8
Beta0.91
Next Earnings
May 06, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.94
Shares Outstanding268,112,150
10 Day Avg. Volume2,788,802
30 Day Avg. Volume2,356,776
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio13.38
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.92
Enterprise Value/Gross Profit5.09
Enterprise Value/Ebitda13.04
Forecast
1Y Price Target
$47.58Price Target Upside8.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital ReturnsExecution of a substantial authorized share repurchase program, with additional buyback authorization, supports shareholder returns and can enhance per-share financial metrics.
Clinical EfficacyPhase III STELLAR-303 showing improved overall survival for zanzalintinib plus atezolizumab versus an approved therapy supports the combination's potential to capture later-line colorectal cancer market share.
Regulatory MilestoneFDA acceptance of the new drug application and assignment of a PDUFA date for zanzalintinib creates a definitive regulatory milestone that could enable approval and expand commercial opportunities in colorectal cancer.
Bears Say
Core Franchise MaturationMaturation of the Cabometyx franchise limits growth contribution from the company's largest product, reducing a key near-term revenue lever.
Reimbursement And Gross-to-net PressuresReimbursement challenges and expected Medicare-related discounts are likely to increase gross-to-net deductions, weighing on reported net product sales.
Rising Operating ExpensesExpanded R&D and commercialization efforts are driving higher operating expenses, which could compress margins if revenue growth does not accelerate.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $32.38 and its highest was $49.62 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $11.52B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is May 06, 2026 which is in 82 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Feb 10, 2026. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.11.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.77.
How many shares outstanding does Exelixis have?
Exelixis has 268,112,150 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.94 in its last earnings report, beating expectations of $0.83. Following the earnings report the stock price went down -0.093%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.58 (8.26% Upside)
$47.58 (8.26% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.27%
12-Months-Change
Fundamentals
Return on Equity
30.56%
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
EXEL Company Deck
EXEL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum driven by CABOMETYX (17% full-year U.S. growth; Q4 growth) and a materially positive regulatory milestone with ZANZA NDA acceptance and a 20% ITT OS benefit in STELLAR-303, supported by a broad pivotal development program and healthy cash plus aggressive share repurchases. Offsetting risks include rising operating expenses, anticipated higher gross-to-net deductions (31–32% guidance for 2026) driven by channel variability and a 2% Medicare Part D discount, and remaining regulatory/clinical uncertainty tied to immature NLM OS data and the outcomes of several pivotal trials. Overall, the positive commercial and pipeline developments and strong balance sheet outweigh the near-term financial and regulatory risks.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$47.58
▲(8.26% Upside)
Technical Analysis
Ownership Overview
3.72% Insiders
24.39% Mutual Funds
0.18% Other Institutional Investors
42.78% Public Companies and Individual Investors